3 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Abrocitinib 100 mg: new trials by email Literature Review of Abrocitinib 100 mg trials Research Report on Abrocitinib 100 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy Abrocitinib 200 mg, Abrocitinib 100 mg, Placebo - Chronic Hand Eczema | Phase 2 | Completed | Innovaderm Research Inc. | 82 | 2024-05-31 | 2026-02-03 |
| A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India Abrocitinib 100 mg, Abrocitinib 200 mg - Atopic Dermatitis | Phase 3 | Completed | Pfizer | 200 | 2022-07-16 | 2024-10-15 |
| Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo - Dermatitis, Atopic | Phase 3 | Completed | Pfizer | 3166 | 2018-03-08 | 2026-01-15 |
Dermatitis, Atopic (3) · Eczema (2)
Pfizer (2) · Innovaderm Research Inc. (1)
Canada (2) · Poland (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Chile (1) · China (1) · Czechia (1) · Finland (1) · Germany (1) · Hungary (1) · India (1) · Israel (1)
PMID 34406619, PMID 39104653, PMID 39903335, PMID 40028832, PMID 42162528, PMID 42365219, PMID 42844558
2023 (1)